Summit Starts Phase III HARMONi-10 Trial in NSCLC
Summit Therapeutics announced the initiation of its global Phase III HARMONi-10 study evaluating ivonescimab versus durvalumab in unresectable stage III NSCLC, aiming to de-risk development. This new trial could significantly impact the company's valuation by advancing its fast-growing pipeline and competing in the lung cancer sector.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed